BCR and B-cell chronic lymphocytic leukemia: In the present study, we focused our investigation on patients with M-CLL, the subgroup of patients most likely to exhibit persistent lymphocytosis during BCR inhibitor therapy [9], and therefore most likely to have more readily detectable functional subclonal heterogeneity.